All In Biotech

Drug Trial Radar · NCT07621718

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 670 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

670

Planned (sponsor's estimate)

Start

May 22, 2026

Primary completion

Dec 30, 2028

Study completion Apr 22, 2030

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

Conditions

  • Pancreatic Cancer
  • Pancreatic Cancer Metastatic
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma
  • Pancreatic Adenosquamous Carcinoma

Interventions

  • ZoldonrasibDrug

    oral tablets

  • PlaceboDrug

    oral tablets

  • OxaliplatinDrug

    IV infusion

  • Leucovorin (Calcium Folinate)Drug

    IV infusion

  • 5-FluorouracilDrug

    IV infusion

  • IrinotecanDrug

    IV infusion

  • Gemcitabine (GEM)Drug

    IV infusion

  • Nab-paclitaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Up to approximately 4 years
  2. Overall survival (OS)Time frame: Up to approximately 4 years

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Recruiting

  • The University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Piedmont Cancer Institute

    Atlanta, Georgia · Recruiting

  • Piedmont Healthcare

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Rutgers Cancer University

    New Brunswick, New Jersey · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Universitatsklinikum der PMU Salzburg Landeskrankenhaus

    Salzburg, Austria · Recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy · Recruiting

  • Instituto Oncologico Veneto - IRCCS

    Padova, Italy · Recruiting

  • Radboud UMC

    Nijmegen, Netherlands · Recruiting

  • St Bartholomew's Hospital - Barts Health NHS Trust

    London, United Kingdom · Recruiting

  • Royal Marsden Hospital

    London, United Kingdom · Recruiting

  • Imperial College Healthcare NHS Foundation Trust - Hammersmith Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.